Program
HXN-1013
A development code.
Its studies are mostly in Asthma, led by Helixon Biotechnology (Suzhou).
Furthest: phase 1, since Oct 21, 20261 company-led study, 1 open or runningNext primary completion: Feb 15, 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Helixon Biotechnology (Suzhou) | 11 open or running | phase 1since Oct 21, 2026 | Oct 21, 2026 | Feb 15, 2028phase 1 · NCT07900568 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 21, 2026First study: phase 1 study in AsthmaFirst studyNCT07900568 · 40 planned · Australia
Ahead
- Feb 15, 2028Primary completion: phase 1 study in AsthmaNCT07900568
TargetBeta
“HXN-1013 is a recombinant humanized bispecific antibody simultaneously targeting thymic stromal lymphopoietin (TSLP) and interleukin-33 (IL-33).”study text, by rule · the study
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| HY6725rule | Newsoara Biopharma | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07900568Asthma · Australia | 1 | Not yet recruiting | Feb 15, 2028 | 40 |
How it is read
Names in the registry
- “HXN-1013”, 1 entry
Codes read as this program: HXN1013.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.